biotech

29 articles about biotech in AI news

Anthropic Acquires AI Biotech Coefficient Bio for ~$400M to Build 'Virtual Biologist'

Anthropic acquired AI biotech startup Coefficient Bio for approximately $400M. The small team was building AI to plan drug R&D, manage clinical strategy, and identify new drug opportunities, aligning with CEO Dario Amodei's vision of AI as a 'virtual biologist.'

95% relevant

The Coming Revolution: How AI-Powered Biotech Could Make Aging Obsolete Within Two Decades

Harvard geneticist David Sinclair predicts biotechnology advances will transform healthcare within 10-20 years, shifting from treating diseases to preventing and reversing aging itself through AI-driven biological control.

85% relevant

Chamath Palihapitiya: SpaceX to Underpin AI-Driven Space Economy

Investor Chamath Palihapitiya stated that SpaceX's infrastructure will allow AI to rebuild every dimension of Earth's economy in space, creating vast new value layers.

85% relevant

Sam Altman Predicts 'One-Person Billion-Dollar Companies' as AI Reshapes Business Scale

OpenAI CEO Sam Altman predicts the emergence of 'one-person billion-dollar companies' powered by AI, citing a specific example from a private CEO discussion group. This follows his earlier forecast of 10-person billion-dollar firms, suggesting AI is accelerating the compression of business scale.

87% relevant

Eli Lilly Signs $2.75B AI Drug Discovery Deal with Insilico Medicine

Eli Lilly has entered a $2.75 billion licensing pact with Insilico Medicine for multiple AI-discovered drug programs. The deal includes an upfront payment, milestones, and royalties, marking a major validation for AI-driven pharmaceutical R&D.

95% relevant

China's Planar Maglev 'XBot' Movers Use AI for 6-DoF Precision on Electromagnetic 'Flyway'

Chinese robotics firm Planar Motor demonstrates 'XBot' movers that levitate 1–2 mm above a tiled electromagnetic surface, achieving frictionless, coordinated 2D motion. The system uses AI for 6-degree-of-freedom precision control in factory automation.

87% relevant

The Situation Game Launches Real-Time Market Instinct Test, Not an AI Trading Simulator

A new web-based game called The Situation tests players' market intuition in real-time against breaking news and a live crowd. It's a free, zero-chart psychological competition, not a trading simulator or AI model.

85% relevant

Kimi Launches 'Kimi Slides' AI Presentation Tool, Claims 5-Minute Investor Deck Creation

Moonshot AI's Kimi chatbot has launched a new feature called Kimi Slides that generates investor-ready presentations from messy notes in 5 minutes, positioning itself against professional design services.

85% relevant

Nature Report: China's Public R&D Spending Nears US Levels, Shifting Global Science Funding Landscape

A new Nature report indicates China is close to surpassing the US in public R&D spending. This shift in funding could alter which nation sets the global pace for scientific research, though China still lags in fundamental research output.

97% relevant

Boston Consulting Group on 'Speaking Your AI Agent’s Language'

BCG highlights the critical need for effective human-AI agent communication as a cornerstone of digital transformation, particularly in complex, regulated industries like life sciences. This principle is broadly applicable to retail.

80% relevant

OpenAI's 'Autonomous AI Researchers' Vision Sparks Debate on Biology's 'ChatGPT Moment'

A tweet highlights OpenAI's repeated references to 'autonomous AI researchers' as signaling a 'ChatGPT moment for biology,' suggesting AI could accelerate drug discovery by orders of magnitude. The claim draws a direct analogy to AlphaFold's impact on structural biology.

85% relevant

Unitree Robotics Files for $610M IPO on Shanghai Star Market After 335% Revenue Surge

Chinese robotics firm Unitree Robotics has filed for a $610M IPO after revenue jumped 335% to 1.71B yuan in 2024. The company shipped over 30,000 quadruped and 5,500 humanoid robots, with humanoids now driving over half its revenue.

83% relevant

Neurons Playing Doom: How Living Brain Cells Could Revolutionize Computing

Australian startup Cortical Labs is pioneering biological computing with a system that uses living human brain cells to perform computational tasks. Their CL1 computer consumes just 30 watts while learning to play Doom, potentially offering massive energy savings over traditional AI hardware.

85% relevant

Anthropic Challenges U.S. Government in Dual Lawsuits Over AI Research Restrictions

AI safety company Anthropic has filed lawsuits in two separate federal courts challenging U.S. government restrictions that have placed its research lab on an export blacklist. The legal action represents a significant confrontation between AI developers and regulatory authorities over research transparency and national security concerns.

85% relevant

The AI-Powered 'Cocktail': How One Injection Could Revolutionize Healthcare by 2029

A leading AI researcher predicts that within five years, personalized medical treatments delivered via single injections or pills will become reality. This breakthrough promises to democratize access to advanced healthcare through AI-driven drug discovery and delivery systems.

85% relevant

Biological Computing Breakthrough: Human Neurons Play DOOM in Petri Dish

Cortical Labs has successfully trained 200,000 human brain cells to play the classic video game DOOM, marking a significant leap toward Synthetic Biological Intelligence. This biological computing approach could solve AI's massive energy consumption problem while enabling new forms of adaptive learning.

95% relevant

Safety Gap: OpenAI's Most Powerful AI Models Released Without Critical Risk Assessments

OpenAI's GPT-5.4 Pro, potentially the world's most capable AI for high-risk tasks like bioweapons research and cyber operations, has been released without published safety evaluations or system cards, continuing a concerning pattern with 'Pro' model releases.

85% relevant

China's Semiconductor Leaders Rally for National AI Chip Alliance Amid Tech War Escalation

China's top semiconductor executives have issued an unprecedented public call for a consolidated national effort to build AI chips, signaling a strategic shift toward self-reliance as U.S. export controls tighten. This coordinated push represents China's most direct response yet to technological containment efforts.

85% relevant

The AI IPO Showdown: OpenAI and Anthropic Prepare for Historic Public Debuts

OpenAI and Anthropic are reportedly planning IPOs in 2025, setting the stage for a historic battle between AI giants. Investors appear to be favoring Anthropic's long-term prospects despite OpenAI's current market dominance.

85% relevant

Beyond General AI: How Liquid Foundation Models Are Revolutionizing Drug Discovery

Researchers have developed MMAI Gym, a specialized training platform that teaches AI the 'language of molecules' to create more efficient drug discovery models. The resulting Liquid Foundation Models outperform larger general-purpose AI while requiring fewer computational resources.

85% relevant

Anthropic CEO Slams OpenAI's Pentagon Deal as 'Safety Theater' in Rare Industry Confrontation

Anthropic CEO Dario Amodei criticized OpenAI's Department of Defense AI partnership as 'safety theater' while revealing the Trump administration's hostility toward his company for refusing 'dictator-style praise.' The comments expose deepening fractures in AI governance approaches.

85% relevant

Top AI Researcher Max Schwarzer Departs OpenAI for Anthropic in Major Industry Shift

Prominent AI researcher Max Schwarzer has left OpenAI to join rival Anthropic, signaling intensifying competition for top talent in the AI sector. The move represents a significant personnel shift between two leading AI labs.

85% relevant

XtalPi's Profit Milestone Signals AI's Transformative Impact on Pharmaceutical Discovery

Chinese AI drug discovery firm XtalPi projects its first annual profit in 2025 following a 193% revenue surge, marking a pivotal moment for AI-driven pharmaceutical research. The company's turnaround demonstrates the commercial viability of AI in accelerating drug development pipelines.

75% relevant

The AI Scare Trade: How Market Fears Are Fueling an Unprecedented M&A Frenzy

A wave of AI-driven disruption is creating an 'AI scare trade' in capital markets, sparking fierce competition between traditional firms and AI startups. This has triggered a surge in mergers and acquisitions as companies race to adapt or acquire the technology reshaping entire industries.

75% relevant

AI Titans Unite: Sam Altman's Public Support for Anthropic Signals Industry-Wide Regulatory Push

OpenAI CEO Sam Altman has publicly declared solidarity with Anthropic amid government scrutiny, signaling unprecedented industry alignment on AI regulation. This coordinated stance could reshape how federal agencies approach oversight of rapidly advancing AI technologies.

85% relevant

FT's AI Risk Chart Sparks Debate: 50% Chance of Human Extinction Versus Abundance

A Financial Times chart showing AI could lead to either human extinction or unprecedented abundance has ignited debate about mainstream recognition of existential risks. The visualization presents a stark 50/50 probability between catastrophic and utopian outcomes.

85% relevant

AI Research Automation Could Arrive by 2027, Raising Security Concerns

New analysis suggests AI systems could fully automate top research teams as early as 2027, potentially accelerating progress in sensitive security domains. This development raises questions about international stability and AI governance.

85% relevant

From $100M to $100: How AI is Driving the Next Diagnostic Revolution

The cost of sequencing a human genome has plummeted from $100 million to under $100 in just 25 years, a milestone powered by AI and automation. This unprecedented price drop signals a coming wave of affordable diagnostic tests that could transform personalized medicine.

85% relevant

From Billion-Dollar Project to Pocket Change: How AI Drove the 10 Million-Fold Drop in Genome Sequencing Costs

The cost of sequencing a human genome has plummeted from $1 billion in 2000 to just $100 today—a 10 million-fold reduction. This unprecedented price collapse, accelerated by AI and automation, is revolutionizing personalized medicine and making genomic data accessible to millions.

85% relevant